Friday, August 19, 2022
Novavax Nuvaxovid™ COVID-19 Vaccine Conditionally Authorized in the European Union for Adolescents Aged 12 Through 17
  SocialTwist Tell-a-Friend  

  • Nuvaxovid™ COVID-19 vaccine is the first protein-based option for adolescents aged 12 through 17 in Europe

GAITHERSBURG, Md., July 5, 2022 /PRNewswire/ -- Novavax,  Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the European Commission (EC) has approved the expanded conditional marketing authorization (CMA) of Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine in the European Union (EU) for adolescents aged 12 through 17. The approval follows the positive recommendation made by the European Medicines Agency's Committee for Medicinal Products for Human Use on June 23, 2022.

"With this authorization, we are extremely pleased to be able to offer our Nuvaxovid COVID-19 vaccine to adolescents in the EU," said Stanley C. Erck, President and Chief Executive Officer, Novavax. "Our protein-based vaccine was developed using an innovative approach to traditional technology and has demonstrated efficacy and safety in both adolescents and adults."

The authorization was based on data from the ongoing pediatric expansion  of PREVENT-19, a pivotal Phase 3 trial of 2,247 adolescents aged 12 through 17 years across 73 sites in the U.S., to evaluate the safety, effectiveness (immunogenicity), and efficacy of Nuvaxovid. In the trial, Nuvaxovid achieved its primary effectiveness endpoint and demonstrated 80% clinical efficacy overall at a time when the Delta variant was the predominant circulating SARS-CoV-2 strain in the U.S.

Preliminary safety data from the trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups, and not considered related to the vaccine. Local and systemic reactogenicity was generally lower than or similar to adults, after the first and second dose. The most common adverse reactions observed were injection site tenderness/pain, headache, myalgia, fatigue, and malaise. There was no increase in reactogenicity in younger (12 to <15 years old) adolescents compared to older (15 to <18 years old) adolescents. No new safety signal was observed through the placebo-controlled portion of the study.

The EC granted CMA for Nuvaxovid to prevent COVID-19 in individuals aged 18 and over in December 2021. In addition to the EC's expanded CMA, India  has granted emergency use authorization in the 12 through 17 year-old population.

Authorization in the U.S.

NVX-CoV2373 has not yet been authorized for use in the U.S. and the trade name Nuvaxovid™ has not yet been approved by the U.S. Food and Drug Administration.

Important Safety Information

  • Nuvaxovid is contraindicated in persons who have a hypersensitivity to the active substance, or to any of the excipients.
  • Events of anaphylaxis have been reported with administration of COVID-19 vaccines. Appropriate medical treatment and supervision should be available in case of an anaphylactic reaction following the administration of the vaccine. Close observation for at least 15 minutes is recommended and a second dose of the vaccine should not be given to those who have experienced anaphylaxis to the first dose of Nuvaxovid.
  • Anxiety-related reactions, including vasovagal reactions (syncope), hyperventilation, or stress‐related reactions may occur in association with vaccination as a psychogenic response to the needle injection. It is important that precautions are in place to avoid injury from fainting.
  • Vaccination should be postponed in individuals suffering from an acute severe febrile illness or acute infection. The presence of a minor infection and/or low-grade fever should not delay vaccination.
  • Nuvaxovid should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
  • The efficacy of Nuvaxovid may be lower in immunosuppressed individuals.
  • Administration of Nuvaxovid in pregnancy should only be considered when the potential benefits outweigh any potential risks for the mother and foetus.
  • The effects with Nuvaxovid may temporarily affect the ability to drive or use machines.
  • Individuals may not be fully protected until seven days after their second dose. As with all vaccines, vaccination with Nuvaxovid may not protect all vaccine recipients.
  • The most common adverse reactions observed during clinical studies were headache, nausea or vomiting, myalgia, arthralgia, injection site tenderness/pain, fatigue, and malaise.

For additional information on Nuvaxovid, please visit the following websites:

About NVX-CoV2373
NVX-CoV2373 is a protein-based vaccine engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. The vaccine was created using Novavax' recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is formulated with Novavax' patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19.  

The Novavax COVID-19 vaccine is packaged as a ready-to-use liquid formulation in a vial containing ten doses. The vaccination regimen calls for two 0.5 ml doses (5 mcg antigen and 50 mcg Matrix-M adjuvant) given intramuscularly 21 days apart. The vaccine is stored at 2 °- 8 ° Celsius, enabling the use of existing vaccine supply and cold chain channels. Use of the vaccine should be in accordance with official recommendations.  

Novavax has established partnerships for the manufacture, commercialization and distribution of NVX-CoV2373 worldwide. Existing authorizations leverage Novavax' manufacturing partnership with Serum Institute of India, the world's largest vaccine manufacturer by volume. They will later be supplemented with data from additional manufacturing sites throughout Novavax' global supply chain.  

About the NVX-CoV2373 Phase 3 Trials
NVX-CoV2373 continues being evaluated in two pivotal Phase 3 trials.  

PREVENT-19 (the PRE-fusion protein subunit Vaccine Efficacy Novavax Trial | COVID-19) is a 2:1 randomized, placebo-controlled, observer-blinded trial to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373 with Matrix-M adjuvant in 29,960 participants 18 years of age and over in 119 locations in the U.S. and Mexico. The primary endpoint for PREVENT-19 was the first occurrence of PCR-confirmed symptomatic (mild, moderate or severe) COVID-19 with onset at least seven days after the second dose in serologically negative (to SARS-CoV-2) adult participants at baseline. The statistical success criterion included a lower bound of 95% CI >30%. A secondary endpoint was the prevention of PCR-confirmed, symptomatic moderate or severe COVID-19. Both endpoints were assessed at least seven days after the second study vaccination in volunteers who had not been previously infected with SARS-CoV-2. In the trial, NVX-CoV2373 achieved 90.4% efficacy overall. It was generally well-tolerated and elicited a robust antibody response after the second dose in both studies. Full results of the trial were published in the New England Journal of Medicine (NEJM).  

The pediatric expansion of PREVENT-19 is a 2:1 randomized, placebo-controlled, observer-blinded trial to evaluate the safety, effectiveness, and efficacy of NVX-CoV2373 with Matrix-M adjuvant in 2,247 adolescent participants 12 to 17 years of age in 73 locations in the United States, compared with placebo. In the pediatric trial, NVX-CoV2373 achieved its primary effectiveness endpoint (non-inferiority of the neutralizing antibody response compared to young adult participants 18 through 25 years of age from PREVENT-19) and demonstrated 80% efficacy overall at a time when the Delta variant of concern was the predominant circulating strain in the U.S. Additionally, immune responses were about two-to-three-fold higher in adolescents than in adults against all variants studied.  

PREVENT-19 is being conducted with support from the U.S. government, including the Department of Defense, the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS), and the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health at HHS. BARDA is providing up to $1.75 billion under a Department of Defense agreement (# MCDC2011-001).  

Additionally, a trial conducted in the U.K. with 14,039 participants aged 18 years and over was designed as a randomized, placebo-controlled, observer-blinded study and achieved overall efficacy of 89.7%. The primary endpoint was based on the first occurrence of PCR-confirmed symptomatic (mild, moderate or severe) COVID-19 with onset at least seven days after the second study vaccination in serologically negative (to SARS-CoV-2) adult participants at baseline. Full results of the trial were published in  NEJM.  

About Matrix-M™ Adjuvant  
Novavax' patented saponin-based Matrix-M adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.  

About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. NVX-CoV2373, the company's COVID-19 vaccine, has received conditional authorization from multiple regulatory authorities globally, including the European Commission and the World Health Organization. The vaccine is currently under review by multiple regulatory agencies worldwide and will soon be under review in the U.S. for use in adults, adolescents and as a booster. In addition to its COVID-19 vaccine, Novavax is also currently evaluating a COVID-seasonal influenza combination vaccine candidate in a Phase 1/2 clinical trial, which combines NVX-CoV2373 and NanoFlu*, its quadrivalent influenza investigational vaccine candidate, and is also evaluating an Omicron strain-based vaccine (NVX-CoV2515) as well as a bivalent Omicron-based / original strain-based vaccine. These vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. 

For more information, visit and connect with us on LinkedIn.  

*NanoFlu identifies a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine candidate produced by Novavax. This investigational candidate was evaluated during a controlled phase 3 trial conducted during the 2019-2020 influenza season. 

Forward-Looking Statements
Statements herein relating to the future of Novavax, its operating plans and prospects, its partnerships, the timing of clinical trial results, the ongoing development of NVX-CoV2373, a COVID-seasonal influenza investigational vaccine candidate, the scope, timing and outcome of future regulatory filings and actions, including Novavax' plans to supplement existing authorizations with data from the additional manufacturing sites in Novavax' global supply chain, additional worldwide authorizations of NVX-CoV2373 for adolescents, the potential impact and reach of Novavax and NVX-CoV2373 in addressing vaccine access, controlling the pandemic and protecting populations, and the efficacy, safety and intended utilization of NVX-CoV2373 are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy applicable regulatory authorities; difficulty obtaining scarce raw materials and supplies; resource constraints, including human capital and manufacturing capacity, on the ability of Novavax to pursue planned regulatory pathways; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities; and those other risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Novavax' Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at and, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Alex Delacroix | 240-268-2022  

Ali Chartan | 240-720-7804

Novavax Logo

Logo -  

More News by PR Newswire India

CGTN: China highlights revitalizing northeast in drive for common prosperity

7Seas Entertainment Limited, launches the Gamer Shorts Mobile Application


SKYPlay and Retrocat signed a contract for a new game's onboarding

Bahrain's Ministry of Electricity and Water Affairs launches tender for 72 MW solar plant

With the World's Top Growth Rate, Yili Group Once Again Secures its Place Among the Top Five

IBM and USTA Announce Multi-Year Partnership Renewal Ahead of 2022 US Open

Clear water, blue sky, lush mountain: Guizhou's efforts in environmental protection pay off

Ecom Express partners with what3words for efficient last-mile deliveries

Outhum Media introduces DOA, a Cloud-Based Ad Booking Platform

Institute of Risk Management announces results for the June 2022 Level- 2 IRMCert Examination in India

EvoluteIQ Wins Gold Stevie® Award in 2022 International Business Awards® parent Copperpod Digital Inc. closes funding with KFC Ventures, ready for rapid acceleration and scale-up

CAUSIS E-Mobility opens Pune office; focuses on delivering electric buses to State Government


Engage with a Sustainable Future through Software-defined Vehicles at Frost & Sullivan's Summit

Subscription Video On Demand Market Growth is Driven by Global Competitive Offering

A leader in the AI-driven Quality Inspection space, Jidoka Technologies eyes robust growth in the FMCG sector after achieving success in the auto industry

Adyen advances in-person payments with the launch of in-house designed terminal range

India Bullion and Jewellers Association Ltd. (IBJA) and All India Gem and Jewellery Domestic Council (GJC) To Set Up 'GoldCraft' - An Integrated Gems, Gold and Jewellery Manufacturing Park at Navi Mumbai

Edvoy continues to expand: new office opening in Hyderabad

Karkinos Healthcare Engages OptraSCAN® Digital Pathology In its Mission of Personalized Cancer Care back with TRIUMPH 2.0: India's largest D&I career fair and recruitment drive

Hisense Unveiled Customized Products for the FIFA World Cup 2022™, Setting Extraordinary Standard for Premium Lifestyle Experiences

Forbes Recognizes AArete as one of World's Best Management Consulting Firms 2022

MoF welcomes the IMF Staff's Statement on Article IV Consultation with the Kingdom in 2022.

GIGABYTE Holds Global Campaign "AERO 16 Relay Challenge" Featuring Color Accurate Laptops For Creators

Picarro Introduces the First Automated Solution for Continuous Ethylene Oxide Monitoring

Nobu Hospitality Celebrates 30th Hotel Milestone with the Nobu Hotel & Residences Tulum


Findability Sciences Recognized on the Inc. 5000 for the Second Time

WorkForce Software Named HR Technology Solution Provider of the Year by the 2022 Stevie® Awards for Great Employers

KPM Analytics Announces First Alveograph for Whole Wheat Flour and Dough Analysis

Climate Vault Expands Global Reach in Strategic Alliance with Bilancia

GWM's First Global Coupe SUV, HAVAL H6 GT Receives Favorable Reviews from Motoring Media

Voltas celebrates India's 75 years of Independence with 'Azadi Mahotsav offer'; launches a bouquet of attractive offers

Voltas launches #HumseDeshKiPehchaan campaign; honours the spirit of blue-collar workforce on Independence Day

BOI Approved New Categories Supporting New Technologies and investment Applications Amounted to US$ 6.2 Billion in First Half 2022 on Strong EV, Digital Projects, BOI Says

Godrej Agrovet launches Mission Red Gram; to touch lives of 50,000 farmers with innovative Bee Hotels

Marlabs identified as a Relevant Provider in the ISG Provider Lens™ Quadrant study on 'Marketing Technology (MarTech) - Solutions and Services 2022'

Manyavar congratulates pride of the nation, The champions of Commonwealth Games 2022

True Corporation Applauded by Frost & Sullivan for Effectively and Efficiently Supporting Customers' Increasing Data Needs with its Telecom Solutions

10th White Page Leadership Conclave 2022 featuring Asia's Power Leaders, Admired & Promising Brands, Asia's Inspirational Leaders, An initiative by White Page International

Soroco Launches First-Ever Task Mining Playbook by Everest Group

Chevrolet India continues to maintain promise to customers

Thailand reinforces Kitchen of the World status with Healthier, Tastier Food of The Future

The Executive Zone announces the launch of new Coworking Space in Chennai

Pearl Academy Bengaluru announces affiliation with Bengaluru City University; now offers degree programs in Fashion, Design and Business

CCTV+: Xi visits northeast China's Liaoning, stressing industrial restructuring, flood control


Forrester: Despite Indian Banks' Continued Focus On Digital, Quality Of Customer Experience Remains Stagnant

India's popular comedy show Amazon Original One Mic Stand by Sapan Verma and OML Entertainment gets a German spin

Ex-Amazon Techie Joins ACKO as VP Engineering, Purple Quarter Spearheaded the Search

SafeTree's Digital Platforms are changing the MSME landscape and Risk Mitigation eco-system in India

Teleperformance hires Anish Mukker as the new CEO of India to implement significant expansion plans

ONLY launches a new athleisure brand called ONLY PLAY offering an exciting range of latest fashion and sportswear trends

This pollution season, a value for money solution by Nirvana Being to convert an existing AC into an air purifier

Air India selects RateGain to become Globally Competitive with Real-time Pricing

Xinhua Silk Road: Peach farmers in E. China's Mengyin embrace peachy lives

S Chand and Company Limited continues robust growth, EBITDA up by 158%

Ontario Teachers' Announces Agreement to Acquire a Significant Majority Stake in Sahyadri Hospitals from the Everstone Group

Xinhua Silk Road: Seraphim awarded silver medal in EcoVadis CSR rating

Premia Partners launches Asia's first USD hedged unit class for Chinese Government Bonds with its Premia China Treasury & Policy Bank Bond Long Duration ETF

Wharton Launches Global MBA Program for Executives Cohort to Virtually Reach Rising Leaders Around the World

Secureworks to Report Second Quarter Fiscal 2023 Financial Results on September 1, 2022

Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational Compound Being Developed for Patients with AML


Dare to be YOU -- XPPen Celebrates its 17th Anniversary with Introduction of An Elevated Mascot Image and A New Series

Canon strikes a chord with the millennial audience through its 'Big Smile' campaign

TraceLink joins AWS Partner Network

Rinus Strydom Joins TraceLink as Chief Revenue Officer

TraceLink Adds Multienterprise Task Management to Healthcare and Life Sciences Industries' First Supply Chain Work Management Solution

The INX Digital Company Reports Second Quarter 2022 Update and Financial Results

Starburst Highlights Impressive Company and Customer Growth, Driven by Rapid Adoption of SaaS Solution Starburst Galaxy

Mecobit Starts New Era in Solar Powered Cryptocurrency Mining

Vision Loss Rehabilitation Canada brings AI-driven diabetic eye screening to rural and Indigenous communities

CrowdStrike Applauded by Frost & Sullivan for Addressing Evolving Cyber Threats with Its Endpoint Security Solutions

Global Pre-Registration of Bless Global Begins

Isos Capital Management Appoints Sheetesh Srivastava as Managing Director, India

Wipro GE Healthcare Collaborates with Boston Scientific to Advance Cardiac Care in India

Protiviti Member Firm in India Acqui-hires Loumus Data Systems; Expands its geographical footprint in India with a new office in Noida

Zoomlion Celebrates Opening of New Material Flagship Industrial Parks

Tentworks Interactive launches their globally anticipated tycoon management style game City Block Builder in India

Mirae Asset Mutual Fund launches two new fund offers (NFOs) on Electric & Autonomous Vehicles and Artificial Intelligence themes; First of its kind to be launched in India

Arman Financial Services Limited declares solid bounce-back performance for Q1FY23 on profitability, asset quality, disbursements and collections

HappyEasyGo launches the 'Big Freedom Sale' to boost travel in August 2022

ExoCoBio's First Global Regenerative Aesthetic Exosome Summit

Omdia: Transformable display market will grow up to 117.7 million units in 2029

AirCarbon Exchange selects Eventus as partner to introduce first comprehensive market surveillance program for Voluntary Carbon Market

CCTV+: Macao government, CMG start new round of cooperation

Accel-funded makes three new senior leadership hires to accelerate revenue growth in the region

Appian Opens India Product Development Center

ICP DAS - BMP will attend MEDICAL MANUFACTURING ASIA 2022 in Singapore

Gobiz KOREA is headed for the 2022 GobizWEEK promotion for global buyers

COSTEP Highlights Manufacturing Workforce Development in Rio South Texas

ViewSonic Kicks off the 2022 ColorPro Award to Capture "Breakthrough" in Photography and Digital Art

Ribbon Announces $52 Million Private Placement Financing Led by Neuberger Berman, JPMorgan Chase & Co., and Swarth Investments Ltd.

New Trading Platform Monsoon Launches to the Public

Media Alert: Supermicro's 3rd Annual Open Storage Summit

Quick Heal joins forces with RevBits to strengthen its cybersecurity portfolio

Tricolour unfurled on the indigenous land rig at MEIL's ICOMM

Cisco Applauded by Frost & Sullivan for Delivering an Integrated Secure Cloud Solution with Its Cisco Umbrella Secure Internet Gateway Packages

Richer People, Poorer Planet: Arçelik calls for greater efficiency at IFA 2022 with the launch of its new cutting-edge technology to enhance sustainable solutions for households

Emeritus Welcomes Higher Ed Leader Mike Malefakis as President of University Partnerships to Expand and Deepen Strategic Partnerships with World-Class Universities

AI Adoption Generates New Business Models and Strengthens Customer Value


BAL Pharma Limited announces Q1FY23 results

DCW continues its solid growth momentum in Q1FY23 - its diversified portfolio defends against volatility. aims at making 75 schools financially literate on this 75th Independence day

CGTN poll: 78.34% of people believe China vitalized world economy

Healthcare technology company Omics Data Automation, Inc. Announces opening of its Facility in Bangalore, India

FOTON Receives Order for 210 units of iBlue EV Vans in Singapore

Huion Unveils a Innovative Bluetooth Pen Tablet with Dual Dial Controllers: Inspiroy Dial 2

Rockwell Automation Study Finds Traceability, Serialization Key Initiatives in APAC Corporate Supply Chain Strategies

Cantor Fitzgerald confirms the death of President Anshu Jain

Har Ghar Tiranga: NIDF, Chandigarh University create Guinness World Record for largest human image of waving National Flag

Automation Anywhere Collaborates with Planet Water India Foundation to Bring Clean Water to Impoverished Communities Across India


Yili Remains the World's Most Valuable Dairy Brand in Brand Finance 2022 Report

Education Cannot Wait Proud to Participate in Global Citizen Festival 2022: Calling on World Leaders and Donors to Empower Girls and End Extreme Poverty Now

Allen Career Institute announces the launch of TALLENTEX 2023; One of the biggest talent search scholarship exams in India

Maple offers 17% off on iPhone 13 this Independence Day

Green Hydrogen & Green Ammonia, Metal & Metal Downstream, and Infrastructure are among the ten industrial projects approved by the HLCA committee of the Government of Odisha



JA Worldwide and JA Africa Announce Partnership with Z Zurich Foundation to Create Bright, Boundless Futures for African Youth

CATL announces its second European battery plant in Hungary

GWM HAVAL DARGO Unveiled in South America, Igniting Passion for Diversified Driving

Rio South Texas: At the Nexus of North American Freight Railways Reports COSTEP


Azure Power ties up with Siemens Gamesa for Supply of Onshore Wind Turbines

"BUILDING LIVES" Return Visit to Affordable Housing Project in Algeria

The Season 7 XCMG Apprentice wraps up at the headquarter of XCMG

International Youth Day 2022: XCMG Apprentice Season 7 Brings Insights and Opportunities of Construction Machinery Industry

NIDF, Chandigarh University to attempt Guinness World Record

Atal Incubation Centre(AIC) NMIMS Inks MoU with


World's leading wine and spirits exhibition now in Mumbai


Intermedia Cloud Communications Wins the Coveted 2022 UC Award for Best UCaaS Solution Provider

Science and Technology Daily: 5G Empowers International Communication Capacity in Multimedia Era

Johnson Controls AI-enhanced OpenBlue Platform Cuts Microsoft's Beijing Campus Energy Footprint

Startek® Wins Silver and Bronze Stevie® Awards in 2022 Stevie Awards for Great Employers

SKYPlay opens pre-registration for Coin Grid prior to the platform's debut

Godrej L'Affaire celebrates #RespectAllBandhans in their touching digital film on the occasion of Raksha Bandhan

Top Organizations Lauded with Prestigious Industry Recognition by Frost & Sullivan for Best-in-Class Performance

Glenmark Pharma reports Revenue of INR 27,773 Mn and PAT of INR 2,111 Mn for Q1 FY 2022-23

Altair Named Official Supplier for Luna Rossa Prada Pirelli Team in its Challenge for the 37th America's Cup

Menarini Group's Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer

Webb Fontaine Announces Launch of Niger National Single Window (NNSW) to Bolster Trade

China's economy becomes the world's economic engine: survey

Hisense's Customized Products for the FIFA World Cup 2022™ Global Launch Event, Advancing Technology for Premium Experience

SotaTek: Real-life Use Cases of Blockchain Adoption that Gets your Mindset Right

Knowledge of Design Week 2022 Presents 'Regeneration by Design'

360tf India office expansion to support exporters in growing their business


Electric Vehicles Lead the Way for Efficient Battery Solutions Globally

FOTON Secures the Biggest Overseas Order of Electric City Buses from Chile

Viasat Expands Footprint in India, Opens New Office in Hyderabad

Nanoprecise Sci Corp Launches NrgMonitor(TM) to Help Customers Reduce their Emissions & Carbon Footprint


Deltek Announces Speakers and Sponsors for Deltek ProjectCon 2022 announces the launch of its proprietary DynamicNLP™, a first in the enterprise Conversational AI space

TUMI announced as Official Luggage Partner of Tottenham Hotspur Women's Pre-Season Tour


NuraLogix researchers announce AI models that can predict Metabolic Risks


CU UCRD's bio-insecticide to revolutionise India's fruit production

No-Code DevOps platform Humalect raises $ 750k in seed round led by StartupXseed Ventures

ONE Advertising - the creative force behind Divya Bhaskar's Sachi Vaat Bedhadak campaign

Sennheiser announced exciting deals on its best-selling products during the Amazon Great Freedom Festival Sale 2022

YES BANK and IBSFINtech tie up to provide enhanced digital services for corporate clients

Multi-Blockchain Wallet App Nufinetes Releases New Feature to View NFTs on Ethereum and VeChain and Aon to help employers improve hiring accuracy, streamlining the end-to-end recruitment process

Shivalik Bimetal posts solid Q1FY23 top and bottom lines YoY, on the back of resurging global demand

Edvoy CEO, Sadiq Basha, named Visionary Entrepreneur of the Year 2022 by WPI

Indo Amines Limited declares tremendous growth, Operational Revenue up by 46%

Over 550,000 people set to attend the International Saudi Falcons and Hunting Exhibition in Malham, Riyadh

HPL Electric and Power Ltd reports solid Q1FY23 Results

Spinny's Take on the Swiftly Changing Automobile Industry

World's Largest Fintech Conference is Back

15th Singapore International Energy Week (SIEW) Registration Now Open

Indian WWW Treatment Market to Experience a Boom as the Country witnesses increase in Private Investments

Khadim India records 190% growth in Retail Sales in Q1 FY 23

Court imposes cost of Rs. 5,000 on prose...
Parliamentary panel on energy may meet t...
No truth in private lab's report on vide...
'Tried to create rift between communitie...
Study files carefully before signing, Ma...
Top Kamtapur liberation movement leader ...
 Top Stories
NZC names strong New Zealand A squa... 
Rape accused who escaped from polic... 
Salman Rushdie's attacker pleads no... 
Shopkeeper stabbed to death in Delh... 
Liz Cheney bruised but undaunted in... 
GPBL: Falcons, Wolves register Supe... 
Congress defers its rally against p... 
Bhima Koregaon case: SC asks trial ...